KEY POINTS
- This methodological review compared international consensus recommendations for palliative radiotherapy trials in bone metastases published in 2002, 2012, and 2026. The authors also audited 39 prospective studies, including 16 randomized trials (41%) and 23 nonrandomized studies, that used International Consensus Pain Response Endpoints. The audit examined whether studies clearly reported eligibility criteria, pain assessment methods, analgesic use, radiotherapy technique, response definitions, and statistical analysis.
- Core pain-response definitions have remained relatively consistent across successive consensus updates. Complete response requires a pain score of zero at the irradiated site without increased analgesic use. Partial response requires either a reduction of at least two points on a 0–10 pain scale without increased analgesics, or an analgesic reduction of at least 25% without increased pain. Pain progression includes a ≥2-point increase with stable analgesics or a ≥25% analgesic increase with stable pain or a one-point increase. Other outcomes are classified as indeterminate response.
- Substantial disagreement remains regarding how pain should be measured. The 2026 consensus favored assessing both worst and average pain in 70% of respondents, but preferred recall periods remained divided between three days (44%) and seven days (51%). Among the 39 audited studies, 13 (33%) did not specify the pain metric. Of the 26 studies reporting it, 23 used worst pain, either alone or with another measure. Such variation makes pain-response rates difficult to interpret consistently across clinical trials.
- More than half of the studies did not report the pain recall period. This information was missing from 20/39 studies (51%). Among studies specifying a recall window, seven used 24 hours, eight used three days, and four used seven days. Recall duration can influence reported symptom severity, particularly when pain fluctuates. The lack of a consistent standard and frequent omission of this information therefore introduce uncertainty into comparisons of palliative radiotherapy effectiveness.
- The 2026 consensus introduced additional methodological recommendations. These included stratification by complicated versus uncomplicated bone metastases (89% agreement), adoption of the ESTRO-ACROP definition of uncomplicated disease (93%), recording adjuvant analgesics (92%), and inclusion of skeletal-related events as trial endpoints (100%). However, recommendations on irradiating vertebral bodies adjacent to the symptomatic level remained unresolved, reflecting persistent uncertainty around target-volume design in the era of conformal treatment.
- Important trial methods were also incompletely reported. Only 23/39 studies (59%) reported using an intention-to-treat analysis, while the same proportion documented concomitant systemic therapy. A run-in period for analgesic optimization was reported in only six studies. Terminology for stable or indeterminate pain response varied substantially. More recent publication year was associated with better reporting of radiation technique (OR for omission 0.22, 95% CI 0.05–0.90) and intention-to-treat analysis (OR 0.21, 95% CI 0.05–0.95), but not with consistent reporting of pain metrics or recall periods.
- The authors proposed a reporting checklist to improve reproducibility in future trials. The checklist emphasizes documenting the pain metric and recall period, baseline eligibility thresholds, analgesic consumption in oral morphine equivalent dose, co-interventions, radiation technique, follow-up schedule, and statistical population. However, the audit assessed what publications reported, not necessarily what investigators performed during trial conduct. It was also restricted to selected studies using established consensus endpoints, and the proposed checklist has not yet undergone independent validation.
CLINICAL TAKEAWAY
Despite more than two decades of international consensus development, palliative radiotherapy trials for bone metastases frequently omit fundamental details needed to interpret pain-response outcomes. Standardized reporting of pain measures, recall periods, analgesic use, and co-interventions is essential for reliable comparison of treatments and evidence synthesis. The proposed checklist may improve methodological transparency, but requires validation and consistent adoption.